智通财经APP获悉，港股未能延续昨日强劲走势，三大指数集体下挫，恒指失守两万二大关，恒科指盘 中一度跌超2%。截止收盘，恒生指数跌0.74%或162.86点，报21909.76点，全日成交额2047.6亿港元； 恒生国企指数跌0.73%，报8056.85点；恒生科技指数跌1.46%，报4975.89点。 华泰证券指出，对等关税扰动发生后，坚定看好港股相对收益表现，原因有三点：第一，产业上，市场 中业绩与关税敏感性较高的出口链及中游制造企业市值占比较低；第二，科技企业盈利表现或将持续支 持港股行情演绎；第三，外部扰动下，市场或对内需政策存在较大预期。 蓝筹股表现 新东方-S(09901)探底回升。截至收盘，涨1.69%，报36.05港元，成交额4.43亿港元，贡献恒指0.67点。 新东方2025财年第三财季收入同比跌2%，教育业务收入同比升21%；股东应占净利润同比上升0.1%至 8726万美元。高盛预期，若公司可在第四财季实现利润率扩张，届时投资者信心将得到改善，估值可望 提升。 2. 内房股多数上扬。截至收盘，融创中国(01918)涨5.06%，报1.66港元；富力地产(02777)涨4.81%，报 1.0 ...

Core Insights - The Chinese innovative drug market is projected to exceed 1.13 trillion yuan in 2024, with expectations to approach 2.3 trillion yuan by 2030, indicating a high growth trend in the sector [1] - The Hong Kong pharmaceutical ETF (159718) has shown a recent decline of 0.28%, but has increased by 7.16% over the past week [1] - The liquidity of the Hong Kong pharmaceutical ETF is active, with a turnover of 17.21% and a transaction volume of 50.91 million yuan [2] Group 1: Market Performance - As of April 24, 2025, notable stock performances include Xintai Medical (02291) up 13.86%, Ascentage Pharma-B (06855) up 7.36%, and Innovent Biologics (01801) up 4.18% [1] - The Medical Innovation ETF (516820) has a recent turnover of 1.7% and a transaction volume of 28.42 million yuan, with an average daily transaction of 53.10 million yuan over the past month [4] Group 2: Index and Weighting - The CSI Hong Kong Stock Connect Healthcare Index (930965) includes 50 liquid and large-cap healthcare companies, with the top ten stocks accounting for 59.76% of the index [6] - The top ten stocks in the CSI Pharmaceutical and Medical Device Innovation Index (931484) account for 66.49%, indicating a concentration in leading companies [9] Group 3: Investment Outlook - The manager of Ping An Healthcare Fund, Zhou Sicong, emphasizes that the export of innovative drugs is largely unaffected by U.S. tariff policies due to factors such as high profit margins and the nature of intellectual property [2] - The innovative drug sector is expected to have a promising outlook for Chinese companies, with investors advised not to overreact to short-term policy fluctuations [2]

Core Viewpoint - The head-to-head trial results of Iwosimab (PD-1/VEGF dual antibody) against the PD-1 therapy from BeiGene demonstrate significant clinical benefits, marking a milestone in the treatment of squamous non-small cell lung cancer (sq-NSCLC) [1][2][3] Group 1: Clinical Trial Results - Iwosimab combined with chemotherapy showed strong positive results compared to BeiGene's Tislelizumab combined with chemotherapy in a pivotal Phase III trial (AK112-306/HARMONi-6) for advanced sq-NSCLC [1] - The trial results indicate statistically significant benefits and major clinical advantages, which are expected to enhance treatment options for sq-NSCLC patients [2][3] - Iwosimab has previously demonstrated a doubling of median progression-free survival (mPFS) in a head-to-head trial against Merck's Keytruda (Pembrolizumab) [2] Group 2: Market Impact and Company Performance - Following the announcement of the trial results, Kangfang Biopharma's stock surged over 10%, reaching a historical high of 100 HKD per share, with a cumulative increase of over 40% in recent times [2] - The sales figures for Tislelizumab are projected to be 3.806 billion CNY in 2023 and 4.467 billion CNY in 2024, indicating its status as a leading domestic PD-1 therapy [2] Group 3: Industry Trends and Innovations - The Chinese innovative drug sector is increasingly taking the lead in lung cancer treatment, with a notable shift from "follower" to "leader" status in various therapeutic areas [6] - The latest National Medical Insurance directory includes 12 new drugs for lung cancer treatment, reflecting the growing innovation in the Chinese pharmaceutical industry [6] - The overall five-year survival rate for late-stage lung cancer patients in China has improved from 5% during the chemotherapy era to 20%-30% currently, although it still lags behind the overall cancer survival rate of 43% [6] Group 4: Future Prospects - Kangfang Biopharma is expected to release international multi-center Phase III clinical data for Iwosimab in 2025, which could lead to a submission for FDA approval if results are positive [8] - The company emphasizes the importance of head-to-head trials to establish the clinical value of new therapies against existing standards [4][5]

文 | 银行螺丝钉 （转载请注明出处） 一、【直播回放】 港股指数基金的品种也越来越丰富。 常见的港股宽基指数，有恒生、H股、港股中小；策略指数，例如港股红利；行业主题指数，例如港股消费、恒生医疗、港股科技、恒生科技等。 这些指数分别有啥特点？影响港股涨跌走势的原因有哪些？ 如何快速查询港股各个指数的估值数据？ 在昨晚的直播课里，螺丝钉详细介绍了这些问题。 长按识别下面二维码，添加 @课程小助手 微信，回复「 0422 」即可观看直播回放。 （提示：回复后可以耐心等待几秒哦～） 策略指数丰富了我们投资的选项，满足了很多投资者个性化的需求。 第三类是行业指数。 也就是仅覆盖了某个行业的股票，例如消费、医药、金融等。 最常见的行业指数，是11个一级行业。 每个一级行业，其实都是社会不可或缺的一部分，长期也是跟着社会发展的。 第四类是主题指数。 二、【部分直播课内容如下】 1. 港股常见的四类指数 跟A股类似，港股常见的指数，主要也分为四类。 第一类是 宽基 指数。 通常是按照上市公司的市值规模来选股的，会包含各个行业的股票，覆盖范围很"宽"。 第二类是 策略指数 。 通常是在宽基指数的基础上，用了某一种投资策略， ...

中银创新医疗混合A股票持仓前十占比合计70.44%，分别为：科伦博泰生（9.77%）、恒瑞医药 （9.39%）、信达生物（8.54%）、康方生物（8.24%）、康诺亚-B（6.59%）、新诺威（6.27%）、百济 神州-U（6.02%）、百利天恒（5.89%）、和黄医药（5.16%）、翰森制药（4.57%）。 金融界2025年4月23日消息，中银创新医疗混合A(007718) 最新净值1.6795元，下跌1.12%。该基金近1个 月收益率18.94%，同类排名9|4629；近3个月收益率42.92%，同类排名15|4571；今年来收益率39.57%， 同类排名21|4554。 简历显示：郑宁先生:中国,研究生、硕士。曾任泰康资产管理有限责任公司股票研究经理、高级股票研 究经理;中庚基金管理有限公司研究员、高级研究员(医药组组长)。2022年加入中银基金管理有限公司。 2022年7月1日担任中银创新医疗混合型证券投资基金基金经理。2022年10月13日担任中银医疗保健灵活 配置混合型证券投资基金基金经理。2023年2月28日任中银大健康股票型证券投资基金基金经理。 来源：金融界 公开资料显示，中银创新医疗混合A ...

热门板块方面 智通财经APP获悉，港股今日低开高走，三大指数午后集体转涨，恒指盘中一度涨近1%。截止收盘， 恒生指数涨0.78%或167.18点，报21562.32点，全日成交额2513.82亿港元；恒生国企指数涨0.68%，报 7950.79点；恒生科技指数涨0.24%，报4899.21点。 华泰证券指出，往前看，对等关税扰动发生后，该行坚定看好港股相对收益表现，原因是：产业上，市 场中业绩与关税敏感性较高的出口链及中游制造企业市值占比较低；科技企业盈利表现或将持续支持港 股行情演绎；外部扰动下，市场或对内需政策存在较大预期。 蓝筹股表现 小米集团-W(01810)表现亮眼。截至收盘，涨5.84%，报44.4港元，成交额122.9亿港元，贡献恒指71.47 点。富瑞研报指出，小米仍是该行中国科技股中的首选股，原因包括：公司具强劲增长，得益于其独特 的生态系统；美国关税料对其业务影响较小；小米并无美国存托凭证(ADR)退市风险。高盛预计YU7仍 能按计划在6月至7月正式发布，维持今明两年YU7销量预测为约8.5万辆及36万辆不变。 其他蓝筹股方面，石药集团(01093)涨8.81%，报6.05港元，贡献恒指6 ...

近日，中国研究型医院学会糖尿病学专业委员会组织编写的《胰高糖素样肽1受体激动剂联合胰岛素治 疗2型糖尿病专家共识(2025版)》在《中华糖尿病杂志》发表，翰森制药聚乙二醇洛塞那肽注射液(商品 名：孚来美)成功纳入推荐，助力2型糖尿病联合治疗革新。 在我国，胰岛素被广泛应用于糖尿病治疗，但低血糖和体重增加是常见且不容忽视的不良反应。胰高糖 素样肽1受体激动剂(GLP-1RA)与胰岛素联合，可针对2型糖尿病(T2DM)多种病理生理缺陷干预，不仅 能显著增强降糖效果，减少每日胰岛素用量，还能降低体重增加和低血糖风险，已成为临床常用联合治 疗方案。《胰高糖素样肽1受体激动剂联合胰岛素治疗2型糖尿病专家共识(2025版)》旨在规范这一联合 治疗方案的临床应用，为基层医师提供科学权威的参考和指导。 共识指出，足量GLP-1RA联合胰岛素，可为患者带来心血管及肾脏保护等额外获益，无论日制剂还是 周制剂，都能显著降低糖化血红蛋白(HbA1c)水平，提高血糖达标率。此外，基于空腹C肽的T2DM分型 为精准治疗提供了便捷途径，GLP-1RA适配不同T2DM分型的精准治疗方案。 孚来美是我国首个自主研发的GLP-1RA周制剂、全球 ...

Group 1 - The Hong Kong pharmaceutical ETF (513700.SH) increased by 3.14%, with major constituents such as Xintai Medical rising by 60%, Meizhong Jiahe by 26%, and Nuocheng Jianhua by 13% [1] - Yuan Da Pharmaceutical announced a milestone breakthrough in its clinical research for the innovative radioactive nuclide-conjugated drug (RDC) GPN02006 for diagnosing hepatocellular carcinoma (HCC), achieving high-quality imaging within 30 minutes of administration [1] - GPN02006 provides strong molecular imaging evidence for personalized treatment plans, addressing the clinical need for rapid diagnosis of HCC and improving early diagnosis rates and monitoring of recurrence and metastasis [1] Group 2 - Guojin Securities believes that innovative drugs in the Hong Kong stock market will be a key investment theme in 2025, driven by AI enabling shorter R&D cycles, reduced costs, and improved efficiency [2] - The recovery of investment and financing activities in the global pharmaceutical industry is beneficial for improving cash flow for innovative drug companies [2] - Anticipation of fiscal stimulus, including the imminent release of the "Class B Directory," may catalyze valuation and sentiment recovery in the sector [2]

Group 1 - The core point of the news is the performance of the Zhongyin Innovation Medical Mixed A fund, which has shown significant growth in its net value and returns over various time frames [1] - As of April 21, 2025, the latest net value of Zhongyin Innovation Medical Mixed A is 1.6127 yuan, reflecting a growth of 2.27% [1] - The fund's one-month return is 14.21%, ranking 9th out of 4672 similar funds; the three-month return is 36.72%, ranking 18th out of 4599; and the year-to-date return is 34.02%, ranking 36th out of 4590 [1] Group 2 - The top ten stock holdings of Zhongyin Innovation Medical Mixed A account for a total of 70.60%, with significant positions in companies such as Heng Rui Pharmaceutical (9.81%), Innovent Biologics (8.55%), and others [1] - The fund was established on November 13, 2019, and as of December 31, 2024, it has a total scale of 2.02 billion yuan [1] - The fund manager, Zheng Ning, has a background in asset management and has held various positions in the industry since 2022 [2]

Group 1 - The core viewpoint of the news is the performance and holdings of the Huatai Fuhua Medical Active Growth One-Year Holding Mixed Fund A, which has shown positive growth in its net value and returns over various time frames [1]. - The latest net value of the fund is 0.5868 yuan, reflecting a growth of 1.58% [1]. - The fund's performance over the past month has yielded a return of 7.20%, ranking 51 out of 4672 in its category [1]. - Over the past three months, the fund has achieved a return of 18.62%, ranking 96 out of 4599 [1]. - Year-to-date, the fund has returned 18.31%, ranking 123 out of 4590 [1]. Group 2 - The top ten stock holdings of the fund account for a total of 47.35%, with significant positions in companies such as Kangfang Biotech (7.08%), Keren Biotechnology (7.04%), and Betta Pharmaceuticals (5.10%) [1]. - The fund was established on August 21, 2020, and as of December 31, 2024, it has a total scale of 1.501 billion yuan [1]. - The fund manager is Zheng Lei, who has extensive experience in the investment management field, having previously worked with various financial institutions [2].